Cargando…

Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions

Amorphous solid dispersions (ASD) are one of the most prominent formulation approaches to overcome bioavailability issues that are often presented by new poorly soluble drug candidates. State-of-the art manufacturing techniques include hot melt extrusion and solvent-based methods like spray drying....

Descripción completa

Detalles Bibliográficos
Autores principales: Hermeling, Malin, Nueboldt, Christoph, Heumann, Roman, Hoheisel, Werner, Breitkreutz, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608596/
https://www.ncbi.nlm.nih.gov/pubmed/36297580
http://dx.doi.org/10.3390/pharmaceutics14102145
_version_ 1784818811020509184
author Hermeling, Malin
Nueboldt, Christoph
Heumann, Roman
Hoheisel, Werner
Breitkreutz, Joerg
author_facet Hermeling, Malin
Nueboldt, Christoph
Heumann, Roman
Hoheisel, Werner
Breitkreutz, Joerg
author_sort Hermeling, Malin
collection PubMed
description Amorphous solid dispersions (ASD) are one of the most prominent formulation approaches to overcome bioavailability issues that are often presented by new poorly soluble drug candidates. State-of-the art manufacturing techniques include hot melt extrusion and solvent-based methods like spray drying. The high thermal and mechanical shear stress during hot melt extrusion, or the use of an organic solvent during solvent-based methods, are examples of clear drawbacks for those methods, limiting their applicability for certain systems. In this work a novel process technology is introduced, called Nano-Dry-Melting (NDM), which can provide an alternative option for ASD manufacturing. NDM consists of a comminution step in which the drug is ground to nanosize and a drying step provides a complete amorphization of the system at temperatures below the melting point. Two drug–polymer systems were prepared using NDM with a wet media mill and a spray dryer and analyzed regarding their degree of crystallinity using XRD analysis. Feasibility studies were performed with indomethacin and PVP. Furthermore, a “proof-of-concept” study was conducted with niclosamide. The experiments successfully led to amorphous samples at temperatures of about 50 K below the melting point within seconds of heat exposition. With this novel, solvent-free and therefore “green” production technology it is feasible to manufacture ASDs even with those drug candidates that cannot be processed by conventional process technologies.
format Online
Article
Text
id pubmed-9608596
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96085962022-10-28 Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions Hermeling, Malin Nueboldt, Christoph Heumann, Roman Hoheisel, Werner Breitkreutz, Joerg Pharmaceutics Article Amorphous solid dispersions (ASD) are one of the most prominent formulation approaches to overcome bioavailability issues that are often presented by new poorly soluble drug candidates. State-of-the art manufacturing techniques include hot melt extrusion and solvent-based methods like spray drying. The high thermal and mechanical shear stress during hot melt extrusion, or the use of an organic solvent during solvent-based methods, are examples of clear drawbacks for those methods, limiting their applicability for certain systems. In this work a novel process technology is introduced, called Nano-Dry-Melting (NDM), which can provide an alternative option for ASD manufacturing. NDM consists of a comminution step in which the drug is ground to nanosize and a drying step provides a complete amorphization of the system at temperatures below the melting point. Two drug–polymer systems were prepared using NDM with a wet media mill and a spray dryer and analyzed regarding their degree of crystallinity using XRD analysis. Feasibility studies were performed with indomethacin and PVP. Furthermore, a “proof-of-concept” study was conducted with niclosamide. The experiments successfully led to amorphous samples at temperatures of about 50 K below the melting point within seconds of heat exposition. With this novel, solvent-free and therefore “green” production technology it is feasible to manufacture ASDs even with those drug candidates that cannot be processed by conventional process technologies. MDPI 2022-10-09 /pmc/articles/PMC9608596/ /pubmed/36297580 http://dx.doi.org/10.3390/pharmaceutics14102145 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hermeling, Malin
Nueboldt, Christoph
Heumann, Roman
Hoheisel, Werner
Breitkreutz, Joerg
Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_full Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_fullStr Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_full_unstemmed Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_short Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_sort nano-dry-melting: a novel technology for manufacturing of pharmaceutical amorphous solid dispersions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608596/
https://www.ncbi.nlm.nih.gov/pubmed/36297580
http://dx.doi.org/10.3390/pharmaceutics14102145
work_keys_str_mv AT hermelingmalin nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT nueboldtchristoph nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT heumannroman nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT hoheiselwerner nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT breitkreutzjoerg nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions